Essential Pharma

UK specialty pharmaceutical company founded in 2000, headquartered in Egham. Holds a growing portfolio of clinically-differentiated niche branded medicines reaching patients in ~70 countries. Focused on rare disease, CNS, ophthalmology and gastroenterology. Completed €900M recapitalisation in December 2024. Acquired Ventavis® (iloprost) from Bayer AG in February 2026.